New York, New York: The Tipline for 6 August 2020
“We’re in the midst of a pandemic” is an excuse that many of us have likely used over the past few months, but one generic drugmaker targeted in the Department of Justice’s price-fixing probe has cited the crisis as a reason for not settling with the agency. Teva Pharmaceuticals chief executive Kare Schultz told Bloomberg yesterday that his company would not sign a deferred prosecution agreement that might “cripple” its ability to supply drugs in the US during covid-19. Also in today’s Tipline, we have a proposed amendment to New York antitrust law that its sponsor says is intended to rein in titans of the technology business, plus the DOJ suing to block a hospital deal and a cartel defence lawyer moving firms.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10